Corpus Intelligence IC Memo — HOSPITAL CAYETANO COLL & TOSTE 2026-04-26 12:35 UTC
IC Memo — HOSPITAL CAYETANO COLL & TOSTE
Investment Committee Memorandum | PR | 160 beds | Grade C | EBITDA uplift $4.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITAL CAYETANO COLL & TOSTE

CCN 400087 | ARECIBO, PR | 160 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOSPITAL CAYETANO COLL & TOSTE is a 160-bed safety-net/medicaid heavy in ARECIBO, PR with $58.3M in net patient revenue and a -11.1% operating margin. The hospital serves a payer mix of 9.0% Medicare, 35.6% Medicaid, and 55.4% commercial.

Thesis: Undervalued. Our ML models identify $4.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -11.1% to -3.7% (+736bps).

Net Revenue HCRIS$58.3M
Current EBITDA COMPUTED$-6.5M
Operating Margin COMPUTED-11.1%
Occupancy HCRIS69.5%
Revenue / Bed COMPUTED$364K
Net-to-Gross HCRIS57.7%
Distress Probability ML55.2%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
37
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -11.1% places it below the state median. Among 37 size-comparable peers (80-320 beds), the median margin is -5.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (80-320), prioritizing same-state peers. 37 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITAL CAYETANO COLL & TOSTE (Target)PR160$58.3M-11.1%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
HOSPITAL DR. ALEJANDRO OTEROPR263$129.0M-1.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
DOCTOR CENTER HOSPITAL MANATI PR258$103.4M1.6%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.2M+210bp18mo
Cost to Collect4.5%2.5%$1.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$709K+122bp9mo
Clean Claim Rate88.0%96.0%$37K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.2M
Cost to Collect
$1.2M
Denial Rate Reduction
$1.2M
A/R Days Reduction
$709K
Clean Claim Rate
$37K
Total EBITDA Uplift$4.3M
Current EBITDA$-6.5M
+ RCM Uplift+$4.3M
Pro Forma EBITDA$-2.2M
Current Margin-11.1%
Pro Forma Margin-3.7%
WC Released (1x)$2.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-10.0M$200K0.00x-100.0%
Base (11x exit)10.0x11.0x$-10.0M$-3.0M0.00x-100.0%
Bull Case9.0x11.0x$-9.0M$7.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-9.0M$6.0M0.00x-100.0%
Bear Case11.0x10.0x$-11.0M$-18.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-11.0M$-23.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (35.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 55.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 37 hospitals with 80-320 beds
  • Same-state prioritization (n=38)
  • Comp margins: P25=-20.7% / P50=-5.7% / P75=1.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.